This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.
I would rather be precise about what I do not know than vague about what I do.
Useful. I had the fact and not the reason, which turns out to be the important half.
Coming back to post #59, because the follow-up matters more than the original answer.
Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.
Small correction to my own earlier position on Research-use-only status. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
Worth separating Research-use-only status as a question about the compound from Research-use-only status as a question about the documentation. They get answered by different people and only one of them is answerable here.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
I had written a reply contradicting post #63 and deleted it. Here is what survived.
The confident answers on Research-use-only status and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Confirming post #67 from a second method, which matters more than confirming it from a second person.
Adding the boring version of Research-use-only status, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Helpful, and short, which on this subject is harder than long.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Peptides with cyclic or disulphide-constrained structures behave differently on a column and differently in solution from linear ones. A purity result should say which the material is.
Worth checking against a second source before it gets quoted onward.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That is my reading. Someone else read the same page differently and was reasonable.
What I can speak to on Research-use-only status is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
I would put a moderate confidence on that and no more.
That is clearer than the version I had in my head. Thank you.
Where I part company with post #75, and it is a narrow parting.
Counterpoint on Research-use-only status, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Picking up post #78: that is the part I would want checked first.
My position on Research-use-only status is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
On post #78 — agreed on the reasoning, with one qualification.
Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing.
I am confident about the direction and much less about the magnitude.
The arithmetic in post #81 is right; the assumption feeding it is the part to check.
Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.
Post #81 put the caveat in the right place and I want to underline it.
I think the Research-use-only status question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Research-use-only status has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Colour in a lyophilised cake is worth noting for the less common compounds specifically, because some of them are genuinely not white and a member expecting white will report a problem that is not one.
The interesting part of this is the exception, and I do not understand the exception.
This is the sort of exchange that makes the archive worth searching.
I read post #85 twice before replying, because I had assumed the opposite.
Having read the whole Research-use-only status thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
This has been discussed before and I could not find the thread, so, again.